Background
Data on the long-term course of neurological immune-related adverse events (n-irAEs) are limited by the size of studies as well as short and heterogeneous follow-up durations. Herein, we assessed the risk and predictors of 1-year neurologic…
Background
Pathologic tumor response and changes in the tumor microenvironment (TME) predict outcomes to immune checkpoint inhibitors, but are understudied in rare tumors. We investigated whether artificial intelligence (AI)-powered analyses of pretre…
Background
The programmed death-ligand 1 (PD-L1) tumor proportion score (TPS) is used as a biomarker to predict benefit from immune checkpoint blockade (ICB) in patients with non-small cell lung cancer (NSCLC). However, additional biomarkers are neede…
by Wang, J., Zhu, Y., He, X., Yin, S., He, Y., Yao, P., Li, J., Li, X., Shi, P., Qian, R., Xiao, Z., Ye, X., Xi, J. J., Ye, B.
Background
Renal cell carcinoma (RCC) frequently exhibits favorable responses to immunotherapy, despite a low tumor mutational burden, suggesting a critical role for non-mutational antigens presented by human leukocyte antigen class I in activating CD…
by Zhu, J., Ye, J., Ma, Y., Lin, Z., Wen, Y., Sheng, J., Yang, M.
Background
Brain metastases (BrM) remain a major cause of mortality in breast cancer (BC), yet the spatial organization and molecular circuitry of the metastatic immune microenvironment are poorly defined.
Methods
To address this gap, we integrated h…
